[Prevention of HLA-alloimmunization of recipients of platelet concentrates].
Over a period of twelve months 7163 HLA-matched, single-donor platelet concentrates were prepared for 557 thrombocytopenic patients with hematologic or neoplastic disorders. 80% of the platelet recipients remained HLA-antibody-negative. Patients who developed HLA-antibodies received random platelets and/or leukocyte-contaminated blood-components simultaneously. Thus, HLA-matching, single-donor-preparations and removal of contaminating leukocytes may prevent HLA-alloimmunisation, and therefore improve the efficacy of platelet-transfusion.
Kuntz
B M
BM
Institut für Blutgerinnung und Transfusionsmedizin, Heinrich-Heine-Universität, Düsseldorf.
Wollenhaupt
H J
HJ
Brüster
H T
HT
D016824:Antigens, Human Platelet / Q000276:immunology*; D016913:Blood Component Transfusion; D001787:Blood Group Incompatibility / Q000097:blood / Q000517:prevention & control*; D001788:Blood Grouping and Crossmatching; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000032:analysis*; D007958:Leukocyte Count; D010976:Platelet Count; D012307:Risk Factors
D016824:Antigens, Human Platelet; D006680:HLA Antigens; D007518:Isoantibodies
Prophylaxe von HLA-Alloimmunisierung bei Empfängern von Plättchen-Konzentraten.